Oak Harvest Investment Services significantly increased its stake in Medtronic PLC (NYSE: MDT) by 34.7% in Q4, bringing its total holdings to 99,435 shares valued at $9.55 million. Medtronic recently outperformed quarterly expectations, reporting $1.36 EPS against an expected $1.34 and revenues of $9.02 billion, and has been given a consensus "Moderate Buy" rating by analysts with a target price of $109.25. Despite an insider sale by EVP Harry Skip Kiil, institutional investors maintain a substantial 82.06% ownership of the company.

Ninety One UK Ltd increased its stake in Aercap Holdings N.V. (NYSE:AER) by 1.1% in the fourth quarter, bringing their total ownership to 2,804,003 shares valued at approximately $403.1 million. This comes after Aercap reported strong Q4 earnings, beating analyst estimates with an EPS of $3.95 and revenue of $2.36 billion, and subsequently raised its quarterly dividend to $0.40 per share. The company maintains a "Moderate Buy" consensus rating from analysts, with an average price target of $153.38.

Ninety One UK Ltd reduced its stake in Monster Beverage Corporation by 13.8%, selling over 1.37 million shares. Despite this sale, Monster Beverage remains a significant holding for the firm and constitutes about 0.88% of its total shares and 1.4% of Ninety One's portfolio. The company recently surpassed Q4 earnings and revenue estimates, and analysts generally maintain a "Moderate Buy" rating for the stock with an average target price of $83.38.

Ninety One UK Ltd increased its stake in Procter & Gamble (NYSE:PG) by 5.2% in the fourth quarter of last year, acquiring an additional 12,496 shares to bring its total holdings to 250,978 shares valued at approximately $35.97 million. Despite insider selling activity, with Chairman Jon R. Moeller offloading a significant number of shares, institutional investors collectively own 65.77% of the stock. Procter & Gamble also raised its quarterly dividend to $1.0885 per share, representing an annualized dividend of $4.35 and a yield of 3.0%.

Ninety One UK Ltd decreased its holdings in Philip Morris International Inc. (NYSE:PM) by 0.6% in the fourth quarter, selling 40,950 shares and retaining 7,151,439 shares valued at approximately $1.147 billion. This makes Philip Morris its 8th largest position, accounting for 2.5% of the fund's total holdings. Key insiders, including CFO Emmanuel Babeau and CEO Jacek Olczak, also significantly reduced their individual stakes during February.

Ninety One UK Ltd significantly increased its stake in Citizens Financial Group (NYSE:CFG) by 13.1% in the fourth quarter, now owning 6,574,714 shares valued at approximately $384 million. This move comes as Citizens Financial Group reported a strong Q1, beating EPS and revenue estimates, and announced a quarterly dividend. Analysts maintain a "Moderate Buy" consensus rating for CFG, with an average target price of $70.90, following several price target increases from research firms.

Ninety One UK Ltd has acquired a new stake of 764,928 shares in Colgate-Palmolive Company (NYSE:CL) during the fourth quarter, valued at approximately $60.45 million. Despite this institutional buying, insiders have been net sellers, disposing of 184,683 shares worth about $17.49 million in the last 90 days. Colgate-Palmolive recently beat quarterly earnings estimates, raised its dividend, and holds a "Moderate Buy" consensus rating from analysts.

Ninety One North America Inc. recently acquired 69,448 shares of Citizens Financial Group (NYSE:CFG) in Q4, valued at approximately $4.06 million, contributing to its already high institutional ownership of 94.90%. Other notable institutional buyers include Ninety One UK, Alyeska, and Zurich, with Zurich significantly increasing its stake by 326.3%. Citizens Financial Group also reported strong Q1 earnings, beating expectations with an EPS of $1.13 and revenue of $2.17 billion, announced a quarterly dividend of $0.46, and received multiple analyst target raises, resulting in a "Moderate Buy" consensus rating and a $70.90 price target.

Ninety One UK Ltd reduced its stake in Delta Air Lines Inc. by 9.2% in Q4, selling 356,049 shares and retaining 3,504,661 shares valued at approximately $243.2 million. This comes as company insiders have also been net sellers, divesting 353,611 shares worth about $25.18 million over the last 90 days. Despite this, Delta Air Lines met Q1 earnings estimates, leading to several analysts raising price targets and a consensus rating of "Moderate Buy."

Pfizer incurred a $4.4 billion impairment charge related to its COVID-19 products as demand declined, prompting a strategic shift. The company is now reallocating R&D efforts towards obesity treatments, backing this with significant investments and a pipeline of 20 upcoming pivotal studies. This move signals a new focus for investors, emphasizing earnings quality, capital allocation, and the progress of these new drug trials over past COVID-driven revenues.